- Email: [email protected]
Correction to Lancet Oncol 2016; 17: 234–42
Corrections
Correction to Lancet Oncol Correction to Lancet Oncol 2016; 17: 234–42 2016; 17: e506 Shaw AT, Gandhi L, Gadgeel S, et al, on behalf of the study investigators. Alectinib in ALK-positive, crizotinibresistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17: 234–42—The appendix of this Article (published Online on Dec 18, 2015) has been corrected as of March 1, 2017.
www.thelancet.com/oncology Vol 18 March 2017
Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol 2016; 17: e502–09—The fourth sentence of the ‘Biosimilar monoclonal antibodies in oncology’ section should have read, “The primary endpoint, overall response rate, at week 24 was equivalent between groups (70% for Myl-1401O vs 64% for trastuzumab), and the risk ratio was 1·09 (90% CI 0·97–1·21). The 90% CI was within the predefined equivalence margin of 0·81–1·24”. This correction has been made to the online version as of March 1, 2017.
e134
Correction to Lancet Oncol Correction to Lancet Oncol 2016; 17: 234–42 2016; 17: e506 Shaw AT, Gandhi L, Gadgeel S, et al, on behalf of the study investigators. Alectinib in ALK-positive, crizotinibresistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17: 234–42—The appendix of this Article (published Online on Dec 18, 2015) has been corrected as of March 1, 2017.
www.thelancet.com/oncology Vol 18 March 2017
Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol 2016; 17: e502–09—The fourth sentence of the ‘Biosimilar monoclonal antibodies in oncology’ section should have read, “The primary endpoint, overall response rate, at week 24 was equivalent between groups (70% for Myl-1401O vs 64% for trastuzumab), and the risk ratio was 1·09 (90% CI 0·97–1·21). The 90% CI was within the predefined equivalence margin of 0·81–1·24”. This correction has been made to the online version as of March 1, 2017.
e134